Module 1 (EU) — Administrative & Summary of Product Characteristics — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The EU administrative content plus the Summary of Product Characteristics (SmPC) — the European drug label.
Why it exists. A European marketing authorization application proposes an SmPC in the standard QRD template. It is the legally approved information for prescribers and is the basis for the patient leaflet.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. eCTD EU regional · QRD template (SmPC)
Module 1 (EU) — Administrative & Summary of Product Characteristics — GLPI-103
| Field | Value |
|---|---|
| Document ID | M1-EU |
| Version | 2.0 (full) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Region | EMA (EU) — MAA Module 1 |
| Standard | eCTD EU regional · QRD template (SmPC) |
| Confidentiality | Confidential |
Region-specific administrative content and the Summary of Product Characteristics (SmPC) per the QRD template. Clinical figures trace to CSR-301 (
outputs/).[MOCK]administrative identifiers.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory Affairs (EU) | Initial Module 1 + SmPC |
| 2.0 | 2026-06-29 | Regulatory Affairs (EU) | Full SmPC — QRD sections 1–10 |
1.0 Cover Letter & Application Form [MOCK]
Virtual Biopharma Inc. submits this Marketing Authorisation Application for GLPI-103 under the centralised procedure. Enclosed: EU application form, proposed SmPC/Annex I, Annex II, labelling, Package Leaflet (with user-consultation/readability test summary), and Modules 2–5. The EU-RMP (RMP-EU) is included.
Summary of Product Characteristics (SmPC)
1. Name of the medicinal product: GLPI-103 solution for injection; GLPI-103 tablets.
2. Qualitative and quantitative composition: Each presentation contains GLPI-103 as the active substance (IV vial; oral tablet with permeation enhancer). For the full list of excipients, see section 6.1 and Module 3.
3. Pharmaceutical form: Solution for injection (intravenous); tablet (oral).
4. Clinical particulars
- 4.1 Therapeutic indications: GLPI-103 is indicated in adults for the treatment of type 2 diabetes mellitus inadequately controlled on metformin, as add-on therapy, to improve glycaemic control.
- 4.2 Posology and method of administration: IV once weekly, titrated 1→2→4 mg (maintenance 4 mg). Oral once daily, titrated 2→4→8 mg (maintenance 8 mg). Titrate to manage gastrointestinal tolerability. Special populations: no dose adjustment anticipated by age/sex; not recommended in severe renal/hepatic impairment (not studied).
- 4.3 Contraindications: Hypersensitivity to the active substance or excipients; personal or family history of medullary thyroid carcinoma or MEN 2.
- 4.4 Special warnings and precautions for use: Acute pancreatitis (discontinue if suspected; do not re-initiate if confirmed); gastrointestinal effects (titration; risk of dehydration); hypoglycaemia in combination with sulfonylurea/insulin (consider reducing the secretagogue/insulin dose); thyroid C-cell monitoring; cardiovascular/heart-rate monitoring (mechanism-related).
- 4.5 Interactions: Delayed gastric emptying may affect absorption of concomitant oral medicinal products; low pharmacokinetic-interaction potential otherwise.
- 4.6 Fertility, pregnancy and lactation: Limited data; not recommended during pregnancy/breast-feeding unless clearly necessary; WOCBP should use effective contraception.
- 4.7 Effects on ability to drive and use machines: Negligible, except in the context of hypoglycaemia.
- 4.8 Undesirable effects: Very common: nausea, vomiting, diarrhoea, decreased appetite. In GLPI103-301 (N=900), nausea occurred in 32.3% (GLPI-103 IV) versus 21.4% (comparator), a non-significant difference; injection-site reactions were more frequent with the IV formulation; hypoglycaemia was infrequent (CSR-301 §12; M2.7.4).
- 4.9 Overdose: Manage symptomatically; gastrointestinal effects expected.
5. Pharmacological properties
- 5.1 Pharmacodynamic properties: ATC code (to be assigned); GLP-1/APJ dual receptor agonist. In the pivotal study, GLPI-103 was superior to oral semaglutide on HbA1c at Week 52 (IV −0.68%, oral −0.34%; both p<0.001), with greater weight reduction and higher responder rates (M2.7.3).
- 5.2 Pharmacokinetic properties: Long half-life (once-weekly IV); oral bioavailability via permeation enhancer; proteolytic catabolism; low immunogenicity (M2.7.2).
- 5.3 Preclinical safety data: Class-consistent; reversible exaggerated-pharmacology effects; thyroid C-cell monitoring; negative genotoxicity (M2.4).
6. Pharmaceutical particulars: excipients, incompatibilities, shelf life, storage, container, and disposal per Module 3.
Annex II / Annex III: conditions of the marketing authorisation (including the RMP-EU and any additional risk-minimisation measures), labelling, and Package Leaflet.
Comments (0)
No comments yet. Be the first to say something!